PhocusWright Conference Honors Magicstay.Com With Launch People's Choice Award
26.11.2019 16:28:00 EET | Business Wire | Press release
On Thursday, November 21, MagicStay won the Launch People's Choice Award at the Phocuswright Conference in Fort Lauderdale, Florida - the world's leading event showcasing the latest technological trends in tourism.
This prestigious award, a veritable acknowledgement of the entire tourism and mobility sector, is a reflection of MagicStay's development strategy, which was put into effect over the past two years on a global scale. With this award, MagicStay has established itself as a key player in Business Travel and mobility on the international stage.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191126005486/en/
A special prize for a special team! #MagicTeam (Photo: Business Wire)
MagicStay, winner of the Launch People's Choice Award
The Launch People's Choice Award recognizes companies which are at least 4 years old and have come up with an innovation that revolutionizes the travel industry. Through this award, the Phocuswright Conference showcases the latest trends and technological innovations in the main sectors of the travel market every year.
In a 10-minute pitch, William Lecerf, co-founder of MagicStay, was able to impress the Dragons - the ten members of the Jury. He received nine positive endorsements in front of around 2,000 of the most influential international experts from the travel industry. The prize was presented to William Lecerf, co-founder (on the left), Valéry Linyer, co-founder and CEO (in the center) and Slobodan Petrovic, COO (on the right).
These 2,000 experts then elected MagicStay.com ahead of twelve competitors previously selected by Phocuswright: Affirm, Airdna, Amadeus, Arrivalist, Cover Genius, HotelRunner, Left Travel, Mistifly, Nezasa, Sift, Kiwi or Travelcompsitor. The prize was awarded jointly to MagicStay.com and Kiwi.
The Dragons' comments were very complimentary:
"You are building a database which offers unique value that no-one else has managed to develop".
Will Philippson,
former Co-founder and COO SilveRail Technologies
"I really like the fact that your content is available in the SBTs".
Charuta Fadnis,
Senior Director Product Strategy and Analytics BCD Travel
"As an expat looking for accommodation in a foreign country, anything you can do to simplify this process is absolutely fantastic. It's an infernal procedure that companies spend a lot of time dealing with and your solution is BRILLANT".
Philip Wolf,
Serial Board Director and Founder Phocuswright Inc.
"I was really impressed by your Duty of Care presentation. As a large company, I know that this issue is one of the biggest fears we have to face when sending our employees abroad on assignments".
Gayle Knolls,
Head of Business Development TRAVELPORT
An effective development strategy
Launched in 2013 in Grasse, the www.MagicStay.com platform devoted its first five years of business to R&D.
After initially focusing on the market of trade show organizers, since 2016 MagicStay has been offering business travelers and, since the beginning of this year, expatriates and/or persons on professional mobility assignments, a secure alternative to professional hotels by responding to duty of care challenges, traveler safety demands and personal data protection, required by large companies.
While broadening its scope, the hosting platform dedicated to professionals has doubled its offer since the beginning of the year. It now has more than 600,000 apartments, villas or apart-hotels available throughout the world (in more than 3,000 cities and 130 countries).
In 2020, MagicStay hopes to reach one million hosting units.
The photo on the previous page and other photos are available on request
MagicStay media library (press releases, logo, photo gallery, etc.)
Join us on: Facebook Twitter LinkedIn
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191126005486/en/
Contact information
MagicStay press contacts:
Fabienne Frédal (AB3C)
Tel. +33 (0)1 53 30 74 07 - fabienne@ab3c.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 12:48:00 EEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
Ant International Launches Industry's First Full-Stack AI-Native Solutions for Payment, Account, FX, Treasury and Growth Operations for Global Businesses18.9.2026 09:53:00 EEST | Press release
In an industry first, Ant International launched a full stack of AI-native solutions for payment, account, FX, treasury and growth operations for global businesses. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260917771311/en/ Peng Yang, CEO of Ant International, introduced the company’s payment foundation model at Ant International's 2026 global merchant event The AI-native product suite is built on a 2-layered security architecture, and our 2 proprietary foundation models: a payment foundation model (Antom 3-in-1 Transformer), and a time-series transformer (TST) forecasting model for FX and liquidity (FalconTST). Underpinning the FinAI stack are also 2 major pillars for payment interoperability for the AI era: our Agentic Mobile Protocol (AMP) and a blockchain-based wholesale settlement platform (WhaleRTP). This round of sweeping product upgrade aims to support all businesses with an AI action plan to complete two critic
Takeda Employees Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health Systems18.9.2026 08:00:00 EEST | Press release
Takeda (TSE:4502/NYSE: TAK) announced that it has awarded a total of USD 22.2 million to four new Global Corporate Social Responsibility (CSR) partners as part of the company’s ongoing commitment to supporting climate-resilient health systems in low- and middle-income countries around the world and aligned with the company’s purpose of better health for people, brighter future for the world. As climate change, extreme weather events and shifting global aid priorities continue to challenge healthcare access, Takeda is advancing its 2026 collaborations with the goal of expanding equitable access, strengthening health system resilience and improving patient outcomes. These efforts focus on locally led solutions that enhance health infrastructure, prepare the healthcare workforce and leverage innovation to sustain essential services for climate-vulnerable communities. “Takeda has made a generational promise to improve health, and for the last 10 years, our Global CSR Program has given our
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom